BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38166029)

  • 1. Comprehensive somatic mutational analysis in glioblastoma: Implications for precision medicine approaches.
    Azimi P; Karimpour M; Yazdanian T; Totonchi M; Ahmadiani A
    PLoS One; 2024; 19(1):e0295698. PubMed ID: 38166029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial.
    Cappelli L; Khan MM; Kayne A; Poiset S; Miller R; Ali A; Niazi M; Shi W; Alnahhas I
    Chin Clin Oncol; 2023 Jun; 12(3):23. PubMed ID: 37417289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
    BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Juglone in Combination with Temozolomide Shows a Promising Epigenetic Therapeutic Effect on the Glioblastoma Cell Line.
    Barciszewska AM; Belter A; Gawrońska I; Giel-Pietraszuk M; Naskręt-Barciszewska MZ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.
    Natsume A; Aoki K; Ohka F; Maeda S; Hirano M; Adilijiang A; Motomura K; Sumi M; Nishikawa R; Narita Y; Muragaki Y; Maruyama T; Ito T; Beppu T; Nakamura H; Kayama T; Sato S; Nagane M; Mishima K; Nakasu Y; Kurisu K; Yamasaki F; Sugiyama K; Onishi T; Iwadate Y; Terasaki M; Kobayashi H; Matsumura A; Ishikawa E; Sasaki H; Mukasa A; Matsuo T; Hirano H; Kumabe T; Shinoura N; Hashimoto N; Aoki T; Asai A; Abe T; Yoshino A; Arakawa Y; Asano K; Yoshimoto K; Shibui S; Okuno Y; Wakabayashi T;
    J Neurooncol; 2020 May; 148(1):17-27. PubMed ID: 32367437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide.
    Saito T; Sugiyama K; Takeshima Y; Amatya VJ; Yamasaki F; Takayasu T; Nosaka R; Muragaki Y; Kawamata T; Kurisu K
    J Neurosurg; 2018 Mar; 128(3):679-684. PubMed ID: 28430038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
    Pellecchia S; De Martino M; Esposito F; Quintavalle C; Fusco A; Pallante P
    Cell Cycle; 2021 Apr; 20(7):716-729. PubMed ID: 33734003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma.
    Nam Y; Koo H; Yang Y; Shin S; Zhu Z; Kim D; Cho HJ; Mu Q; Choi SW; Sa JK; Seo YJ; Kim Y; Lee K; Oh JW; Kwon YJ; Park WY; Kong DS; Seol HJ; Lee JI; Park CK; Lee HW; Yoon Y; Wang J
    Genome Med; 2023 Mar; 15(1):16. PubMed ID: 36915208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic pathways and glioblastoma treatment.
    Clarke J; Penas C; Pastori C; Komotar RJ; Bregy A; Shah AH; Wahlestedt C; Ayad NG
    Epigenetics; 2013 Aug; 8(8):785-95. PubMed ID: 23807265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
    Feng SW; Wu ZS; Chiu YL; Huang SM
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
    Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
    Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients.
    Ene CI; Cimino PJ; Fine HA; Holland EC
    Neurosurg Focus; 2020 Oct; 49(4):E11. PubMed ID: 33002863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of genetic alterations by whole-exome sequencing with clinical outcomes of glioblastoma patients from the Lebanese population.
    Saadeh FS; Morsi RZ; El-Kurdi A; Nemer G; Mahfouz R; Charafeddine M; Khoury J; Najjar MW; Khoueiry P; Assi HI
    PLoS One; 2020; 15(11):e0242793. PubMed ID: 33237934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
    Han J; Puri RK
    J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
    Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
    Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
    Rahman R; Trippa L; Alden S; Fell G; Abbasi T; Mundkur Y; Singh NK; Talawdekar A; Husain Z; Vali S; Ligon KL; Wen PY; Alexander BM
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):716-724. PubMed ID: 32417407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in the Therapeutic Strategies of Glioblastoma Multiforme.
    Aldoghachi AF; Aldoghachi AF; Breyne K; Ling KH; Cheah PS
    Neuroscience; 2022 May; 491():240-270. PubMed ID: 35395355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Targeting of Transcription and Metabolism in Glioblastoma.
    Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
    Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.